share_log

沃森生物(300142.SZ):与艾博生物终止新冠和带状疱疹mRNA疫苗技术开发合作

Walvax Biotechnology (300142.SZ): Terminates COVID-19 and herpes zoster mRNA vaccine technology development cooperation with Eibo Biotechnology.

Zhitong Finance ·  Jun 25 08:42

Walvax Biotechnology (300142.SZ) announced that on June 24, 2024, the company held its fifth Board of Directors meeting...

Watson Biotechnology (300142.SZ) announced that on June 24, 2024, the company held its 19th meeting of the fifth Board of Directors to deliberate and approve the motion on "Termination Agreement" regarding the termination of the technology development cooperation of novel coronavirus mRNA vaccines and herpes zoster mRNA vaccines with Suzhou Abogen Biosciences Co., Ltd. The Board agreed that the Company and its subsidiary, Yuxi Watson Biotechnology Co., Ltd. ("Yuxi Watson"), should terminate the technology development cooperation of novel coronavirus mRNA vaccines and herpes zoster mRNA vaccines with Suzhou Abogen Biosciences Co., Ltd. ("Abogen Biosciences"), and sign the Termination Agreement.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment